Pyrexar Medical In The News

ORB Healthcare signs contract with Pyrexar Medical

PYREXAR HT Hyperthermia products find distribution with ORB Corporation

SALT LAKE CITY, UT,  --  Pyrexar Medical, the makers of PYREXAR HT Hyperthermia-based cancer treatment systems, announced today it is expanding into Central Asia under the help and guidance of ORB Healthcare, a division of ORB Global Ltd.

Hyperthermia is a type of cancer treatment in which tumors are exposed to elevated body temperatures between 40°C and 45°C. Research has shown that these high ‘fever temperatures’ can damage and kill cancer cells with little to no impact on normal tissues. Since hyperthermia increases blood flow, the result is increased oxygen levels in tumor cells, making them more sensitive to radiation. Hyperthermia has been a vital tool in the fight against cancer and higher clinical response is achieved when hyperthermia is combined with radiotherapy and chemotherapy.

ORB has been selected as the exclusive distribution partner of the PYREXAR HT line of hyperthermia products in several markets across Europe and Asia, including Turkey, Kazakhstan and Azerbaijan. “We are very pleased to have ORB Global as a distribution partner. This five million dollar agreement demonstrates their commitment to fighting cancer around the world.” says Mark Falkowski, CEO of Pyrexar Medical. “ORB is a rapidly rising star in the healthcare industry and we look forward to their expertise in these new markets”.

“We have experience in the hyperthermia marketplace and were looking for a more progressive partner who would help take this beneficial therapy to new heights”, says Mr. Golsharifi, CEO of ORB Global, “We chose Pyrexar based on the company’s highly experienced senior executive team, their commitment to product innovation, and their commitment to support the growing hyperthermia community”. ORB plans to work closely with government officials, hospitals, private clinics and a range of oncologists and physicians in order to expand the positive impact of hyperthermia. In addition to Central Asia, they will also represent Pyrexar in the United Kingdom, Japan and Western Asia.

ORB Corporation exists to help meet the energy, healthcare & pharmaceutical, food & agricultural, and IT & networking needs of a rapidly changing world. ORB strives to find, extract, trade, refine, store and transport materials and resources from where supply is abundant to where demand is great. With offices located in the UK, Turkey, Iran, UAE, Japan, Canada, Hong Kong and China, they will continue to forge new connections, make things happen, and help markets work.

Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity of healthy tissues. For more information please visit our web page at: